<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03579732</url>
  </required_header>
  <id_info>
    <org_study_id>19882</org_study_id>
    <nct_id>NCT03579732</nct_id>
  </id_info>
  <brief_title>EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - Taiwan</brief_title>
  <acronym>ENgAGE-Taiwan</acronym>
  <official_title>EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the protective effect of low-dose aspirin use on gastrointestinal cancers
      (colorectal, esophageal and gastric cancers) in long-term users, episodic users and non-users
      of aspirin in Taiwan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to investigate the protective effect of long-term low dose use of
      aspirin on colorectal, esophageal and gastric cancer in adult subjects from Taiwan.

      Secondary objectives are to evaluate the protective effect by duration of low-dose aspirin
      use on colorectal cancer, the effect of discontinuation of aspirin on colorectal cancer
      prevention, the staging distribution of colorectal cancer and the description of fatal cases
      due to colorectal cancer.

      Aspirin use will be identified through Taiwanese National Health Insurance (NIH) data from
      2000 to 2015. Cancer cases and staging of the three cancer types will be ascertained through
      the Taiwan Cancer Registry, using data from 2000 to 2014. Fatal cases will be ascertained
      using Mortality database from 2000 to 2015.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with colorectal cancer</measure>
    <time_frame>Up to 14 years</time_frame>
    <description>Number of subjects with colorectal cancer for each cohort (long-term, episodic and former users of aspirin, and non-users).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with esophageal cancer</measure>
    <time_frame>Up to 14 years</time_frame>
    <description>Number of subjects with esophageal cancer for each cohort (long-term, episodic and former users of aspirin, and non-users).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with gastric cancer</measure>
    <time_frame>Up to 14 years</time_frame>
    <description>Number of subjects with gastric cancer for each cohort (long-term, episodic and former users of aspirin, and non-users).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of aspirin use to colorectal cancer</measure>
    <time_frame>Up to 14 years</time_frame>
    <description>The duration of low-dose aspirin use in years to colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from aspirin discontinuation to colorectal cancer</measure>
    <time_frame>Up to 14 years</time_frame>
    <description>Period of time in years from discontinuation of aspirin use to detection of colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage of colorectal cancer</measure>
    <time_frame>Up to 14 years</time_frame>
    <description>The stage of cancer will be determined according to the International Classification of Diseases for Oncology (ICD-O-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fatal cases due to colorectal cancer</measure>
    <time_frame>Up to 14 years</time_frame>
    <description>Derived from Taiwan Mortality database.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">4710504</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Long-term users</arm_group_label>
    <description>Adults using low-dose aspirin for &gt; 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Episodic users</arm_group_label>
    <description>Adults using low-dose aspirin inconsistently, or consistently but &lt; 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Former users</arm_group_label>
    <description>Subset of adult Episodic users of aspirin who discontinued the drug for at least 1 year before case/ control date</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-consumers</arm_group_label>
    <description>Adults who did not use low-dose aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin (Acetylsalicylic Acid, BAYE4465)</intervention_name>
    <description>Low dose of aspirin, i.e. &lt; 150 mg daily</description>
    <arm_group_label>Episodic users</arm_group_label>
    <arm_group_label>Former users</arm_group_label>
    <arm_group_label>Long-term users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No drug</intervention_name>
    <description>Non-consumers</description>
    <arm_group_label>Non-consumers</arm_group_label>
    <other_name>No aspirin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be selected from the Taiwanese National Health Insurance (NIH) database.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40 or older at the cohort entry date.

          -  Taiwanese National Health Insurance enrollees with non-missing and consistent age and
             gender information.

        Exclusion Criteria:

          -  Subjects with any cancer diagnosis before cohort entry date.

          -  No use of National Health Insurance before the cohort entry date.

          -  Low dose aspirin prescription before cohort entry date.

          -  Subjects with conditions contra-indicated for low dose aspirin use before cohort entry
             date.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National University of Taiwan Hospital</name>
      <address>
        <city>Taipeh</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low-dose aspirin,</keyword>
  <keyword>Cancer prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

